“The data also paves the way for a very quick mo
Post# of 153986
(Total Views: 561)
Posted On: 02/08/2020 12:29:58 AM
“The data also paves the way for a very quick monotherapy approval without additional trials...”
I’ll admit, this sounds appealing, but I believe it’s a pipe dream. NP loves to share information with CYDY investors, down to week by week reports of labs and rads from the cancer patients. I feel if the FDA had hinted to NP that they might approve combo and mono using the combo trial data and CD03 trial data, he would’ve mentioned it. Heck, even if NP felt that this scenario could happen he would’ve mentioned it, multiple times. Why do I think this? Because NP talks about everything, including a possible triple digit PPS, the potential for a billion dollar NASH deal, and chances for multiple debt financing offers. He can’t keep his lips sealed.
If this came from the article you referenced, then this article itself is not much different from the shorts article. Why? Because the author is spreading opinions and claims not backed by facts. Basically there should be a whole lot of “IMOs” in this article.
IMO, of course.
I’ll admit, this sounds appealing, but I believe it’s a pipe dream. NP loves to share information with CYDY investors, down to week by week reports of labs and rads from the cancer patients. I feel if the FDA had hinted to NP that they might approve combo and mono using the combo trial data and CD03 trial data, he would’ve mentioned it. Heck, even if NP felt that this scenario could happen he would’ve mentioned it, multiple times. Why do I think this? Because NP talks about everything, including a possible triple digit PPS, the potential for a billion dollar NASH deal, and chances for multiple debt financing offers. He can’t keep his lips sealed.
If this came from the article you referenced, then this article itself is not much different from the shorts article. Why? Because the author is spreading opinions and claims not backed by facts. Basically there should be a whole lot of “IMOs” in this article.
IMO, of course.
(0)
(0)